Status: Recruiting
A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents
This is an open-label, multicenter, first-in-human dose-escalation and expansion Phase 1-2 study designed to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of OR502 administered as a monotherapy and in combination with cemiplimab in subjects with advanced solid tumors.
Participants needed: 168
Trial details
Phase: Phase 1, Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: OncoResponse, Inc.Updated: Jan 7, 2025Locations: 4
Eligibility criteria
Informed consent signed by the subject prior to conducting study-specific proced... [+13]
Subject previously had a severe hypersensitivity reaction to treatment with anot... [+28]